TSHA
Taysha Gene Therapies (TSHA) Stock Valuation
Review Taysha Gene Therapies (TSHA) valuation with server-rendered company data, supporting context and links to related investor research.
- Price to earnings
- 0
- Price to book
- 6.1
- Dividend yield
- 0%
- Return on equity
- 0%
- BTI fair market cap
- $42.36M
- Premium or discount
- 4,495.91%
- Market cap
- $1.95B
Taysha Gene Therapies (TSHA) Stock Valuation research
The Taysha Gene Therapies valuation page presents the available multiples, profitability measures and BTI fair-value context for TSHA. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.